ReviewBreast cancer (Dove Medical Press)2022

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.

Nusayba A Bagegni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.